Notification
No new Notification messages
Enviro Infra Engineers IPO is Open!
Apply for the Enviro Infra Engineers IPO through UPI in just minutes.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Sun Pharma Q2 Results FY24-25 Highlights: Cons Revenue at ₹13,264 Cr PAT at ₹3,040 Cr

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Sun Pharma reported strong Q2 FY24-25 results with consolidated revenue of ₹13,264 Cr, up 10.5% YoY, and Profit After Tax (PAT) of ₹3,040 Cr, a 28% YoY growth. The company achieved significant growth across multiple regions, especially in the US and specialty segments.

Key Highlights/Quick Insights

  • Revenue: ₹13,264 Cr, marking a 10.5% YoY growth.
  • PAT: ₹3,040 Cr, up 28% YoY.
  • India Formulations: ₹4,265 Cr, up 11% YoY.
  • US Formulations: $517 Mn, reflecting a 20.3% YoY growth.
  • EBITDA: ₹3,939 Cr, with a 29.6% margin, up 23.9% YoY.
  • R&D Investment: ₹793 Cr, focusing on innovation and new product development.

SUN PHARMACEUTICAL IND L

Trade

1795.315.30 (0.85 %)

Updated - 22 November 2024
1814.95day high
DAY HIGH
1768.05day low
DAY LOW
1420813
VOLUME (BSE)

Quarterly - Sun Pharma Q2 Results FY24-25

Sun Pharma’s Q2 FY25 results show impressive performance, with revenue of ₹13,264 Cr and PAT of ₹3,040 Cr, highlighting the company’s strategic focus on growth in both domestic and international markets. The quarter witnessed robust sales in India and the US, supported by specialty product performance.

Financial Metric

Q2 FY25

Q2 FY24

YoY Growth

Revenue from Operations (₹ Cr)

13,264

12,003

10.50%

US Formulations Revenue (USD Mn)

517

430

20.30%

India Formulations Revenue (₹ Cr)

4,265

3,842

11%

Employee Benefits Expense (₹ Cr)

2,478

2,364

4.80%

R&D Expenses (₹ Cr)

793

773

2.50%

EBITDA (₹ Cr)

3,939

3,177

23.90%

EBITDA Margin (%)

29.6

26.5

+3.1 pp

PAT (₹ Cr)

3,040

2,375

28%

Earnings Per Share (EPS) (₹)

12.7

9.9

28.30%

Segment Highlights

In Q2 FY25, India Formulations led domestic revenue growth with ₹4,265 Cr, an 11% YoY increase, supported by new product launches. The US Formulations segment achieved $517 Mn in revenue, driven by specialty products and market expansion. The API segment reported external sales of ₹534 Cr, reflecting a 7.4% increase.

Sector Expectations for Sun Pharma Q2 Results FY24-25

Sun Pharma’s results are in line with sector expectations, especially in the US formulations segment, showcasing resilience and strong demand. The company’s sustained revenue and PAT growth positions it favorably among industry peers, supported by strategic investments in R&D.

Management Commentary

Dilip Shanghvi, Chairman and Managing Director, highlighted, “Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercializing late-stage candidate Fibromun, upon approval. With Fibromun, our product basket for dermatologists has expanded further. We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market.”

Conclusion

Sun Pharma’s Q2 FY25 results underscore a strong operational and financial performance with revenue of ₹13,264 Cr and PAT of ₹3,040 Cr. The company’s continued focus on innovation and expansion in specialty and emerging markets sets a promising outlook for the future.

Check out Sun Pharma's past performances in previous quarters and financial years.  

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text